Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
Page 2

Furthermore, it is also noted that suitable bioequivalence methods are lacking for many generic ophthalmic formulations, including suspensions and emulsions. Therefore an investigation of the relationship between various physicochemical properties and their effect on ocular bioavailability will help the FDA in establishing guidelines for the determination of bioequivalence of ophthalmic suspensions and emulsions.

The scope of the program will cover two types of inquiries:

a) In vitro study – Formulations with different physicochemical properties are manufactured using a selected steroid and characterized in vitro. Drug release and stability tests are conducted to understand how differences in physicochemical properties may affect ocular bioavailability.

b) In vivo study – Formulations selected based on the results of the in vitro study are tested in an animal model. A pharmacokinetic study should be conducted by assessing the ocular distribution of the steroid in various eye tissues and organs at various time points.

In order to support these initiatives, the Food and Drug Administration is set to administer funds in the amount of $400,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The United States Department of Health and Human Services, the mother agency funding the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program, is country's premiere agency for protecting the health of all Americans and providing essential human services, especially to those who medically challenged and vulnerable.

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---

HRSA: Reducing Loss to Follow-up after Failure to Pass Newborn Hearing Screening
Reducing to Loss of Follow-up after Failure to Pass Newborn Hearing Screening program enables eligible health care institutions to solicit funds by establishing project proposals that would greatly improve the number of infants receiving appropriate and timely follow-ups through the utilization of patient-centered interventions.

---

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
In line with this mission, the United States Department of Defense has recently established the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program in an attempt to financially support the studies regarding the promotion innovative research focused on decreasing the clinical impact of tuberous sclerosis complex (TSC).

---

Research to Advance Vaccine Safety Program
The Centers for Disease Control and Prevention has partnered with the National Institutes of Health and as a result, has developed the Research to Advance Vaccine Safety Program, wherein it seeks to obtain a more thorough understanding vaccine safety.

---